Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.

Archives of pharmacal research - 1 Feb 2026

Seok Joohee, Kang Nahyun, Lee Je Jin, Cho Chang-Keun, Lee Yun Jeong

Abstract excerpt

Doxepin, a tricyclic antidepressant, exhibits substantial interindividual variability in pharmacokinetics, mainly attributable to genetic polymorphisms of cytochrome P450 (CYP) enzymes, particularly CYP2D6. Such variability may lead to clinically relevant differences in drug exposure, therapeutic response, and adverse effects when doxepin is used for antidepressant therapy. The present study aimed to develop and...

Topics

Join the communities discussing this publication.

Antidepressive Agents
Antidepressive Agents, Tricyclic
Cytochrome P-450 CYP2D6
Genotype
Models, Biological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polymorphism, Genetic

Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 41758322
DOI: 10.1007/s12272-026-01600-5
PMCID: PMC12999657

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.PMID 41758322Read ↗

Doxepin Drug-Drug and Drug-Gene Interactions: Clinical Implications and Mechanistic InsightsSemantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data.Semantic proximity Read ↗

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.Semantic proximity Read ↗

A Digital Twin of Glimepiride for Personalized and Stratified Diabetes TreatmentSemantic proximity Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.Semantic proximity Read ↗

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.Semantic proximity Read ↗

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.Semantic proximity Read ↗

Cytochrome P450 2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.